成人经鼻咪达唑仑抗癫痫治疗的有效性与耐受性:系统评价
该研究系统检索Embase与Medline,纳入1985至2022年发表的随机试验和队列研究(排除病例系列),评估成人(≥18岁)经鼻咪达唑仑(in-MDZ)治疗癫痫、癫痫发作或癫痫持续状态的有效性与耐受性。共纳入12项研究、929例接受in-MDZ治疗的个体,多数为回顾性研究;单次给药剂量2.5~20 mg。首次in-MDZ给药后癫痫终止的平均比例为72.7%(标准差18%),癫痫复发或持续发作的比例为61%~75%;最常见不良反应为头晕(均值23.5%[标准差38.6%])、意识模糊(1项研究;17.4%)、局部刺激(均值16.6%[标准差9.6%])和镇静(均值12.7%[标准差9.7%])。作者结论认为,in-MDZ似乎对成人延长性癫痫发作和癫痫丛集性发作有前景,有限证据提示经鼻给药是安全的,但因队列异质性、剂量差异及成功终止定义不统一,需进一步研究。
要点
- 成人经鼻咪达唑仑单次剂量2.5~20 mg,首次给药后癫痫终止的平均比例为72.7%(标准差18%)。
- 癫痫复发或持续发作的比例为61%~75%,提示部分患者单次经鼻给药后仍需进一步处理。
- 最常见不良反应为头晕(均值23.5%[标准差38.6%])、局部刺激(均值16.6%[标准差9.6%])、镇静(均值12.7%[标准差9.7%]),意识模糊见于1项研究(17.4%)。
- 纳入研究多数为回顾性,队列异质性大、剂量差异大、成功终止定义不统一,作者认为需进一步研究。
- 作者结论认为经鼻咪达唑仑对成人延长性癫痫发作和癫痫丛集性发作似乎有前景,有限证据提示经鼻给药安全。
适用人群与场景
- 成人患者(≥18岁),因癫痫、癫痫发作或癫痫持续状态接受经鼻咪达唑仑治疗。
- 纳入随机试验和队列研究,排除病例系列;发表语言为英语,发表时间1985至2022年。
处置流程与药物剂量
- 经鼻咪达唑仑单次给药剂量范围为2.5~20 mg。
研究设计与关键结果
- 系统评价共纳入12项研究、929例接受经鼻咪达唑仑治疗的个体;多数研究为回顾性,研究数量随时间增加。
- 首次经鼻咪达唑仑给药后癫痫终止的平均比例为72.7%(标准差18%)。
- 癫痫复发或持续发作的比例为61%~75%。
- 最常见不良反应:头晕均值23.5%(标准差38.6%),意识模糊1项研究17.4%,局部刺激均值16.6%(标准差9.6%),镇静均值12.7%(标准差9.7%)。
- 经鼻咪达唑仑单次给药剂量范围为2.5~20 mg。
证据类型、等级与局限
- 证据类型:系统评价,纳入随机试验和队列研究(排除病例系列)。
- 偏倚风险采用Cochrane偏倚风险工具评估。
- 局限:多数研究为回顾性;队列存在异质性;剂量存在差异;成功癫痫终止的定义缺乏统一性;作者指出需进一步研究。
对床旁实践的改变
- 作者结论认为,经鼻咪达唑仑对成人延长性癫痫发作和癫痫丛集性发作似乎有前景,有限证据提示经鼻给药是安全的。
- 作者指出,由于队列异质性、剂量差异及成功终止定义不统一,需进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: The objective of this study was to assess the efficacy and tolerability of intranasal midazolam (in-MDZ) administration for antiseizure treatment in adults.
METHODS: Embase and Medline literature databases were searched. We included randomized trials and cohort studies (excluding case series) of adult patients (≥ 18 years of age) examining in-MDZ administration for epilepsy, epileptic seizures, or status epilepticus published in English between 1985 and 2022. Studies were screened for eligibility based on predefined criteria. The primary outcome was the efficacy of in-MDZ administration, and the secondary outcome was its tolerability. Extracted data included study design, patient characteristics, intervention details, and outcomes. Risk of bias was assessed using the Cochrane Risk of Bias Tool.
RESULTS: A total of 12 studies with 929 individuals treated with in-MDZ were included. Most studies were retrospective, with their number increasing over time. Administered in-MDZ doses ranged from 2.5 to 20 mg per single dose. The mean proportion of successful seizure termination after first in-MDZ administration was 72.7% (standard deviation [SD] 18%), and the proportion of seizure recurrence or persistent seizures ranged from 61 to 75%. Most frequent adverse reactions to in-MDZ were dizziness (mean 23.5% [SD 38.6%]), confusion (one study; 17.4%), local irritation (mean 16.6% [SD 9.6%]), and sedation (mean 12.7% [SD 9.7%]).
CONCLUSIONS: Administration of in-MDZ seems promising for the treatment of prolonged epileptic seizures and seizure clusters in adults. Limited evidence suggests that intranasal administration is safe. Further research is warranted because of the heterogeneity of cohorts, the variation in dosages, and the lack of uniformity in defining successful seizure termination.
参考来源
- Dittrich TD, Vock D, Fisch U, et al. Efficacy and Tolerability of Intranasal Midazolam Administration for Antiseizure Treatment in Adults: A Systematic Review. Neurocrit Care. 2024. PMID: 38580802. doi:10.1007/s12028-024-01971-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。